• Eikon posted a press release on seven abstracts accepted for presentation at the 2026 ESMO Congress in Madrid.
• Updates span EIK1001 in stage IV NSCLC, EIK1003 in advanced solid tumors and metastatic prostate cancer, EIK1004 in HRR-mutated tumors.
• Early data also cover EIK1005, a WRN helicase inhibitor, including safety, tolerability, pharmacokinetics, monotherapy and pembrolizumab combination results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eikon Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607200800PRIMZONEFULLFEED9764472) on July 20, 2026, and is solely responsible for the information contained therein.